Published January 13, 2025
| Version v1
Journal article
Open
Enabling tumor-specific drug delivery by targeting the Warburg effect of cancer
Creators
- 1. University of Chicago
- 2. Sheba Medical Center
- 3. East China University of Science & Technology
- 4. University of California, Irvine
Description
Metabolic reprogramming of tumor cells is an emerging hallmark of cancer. Among all the changes in cancer metabolism, increased glucose uptake and the accumulation of lactate under normoxic conditions (the "Warburg effect") is a common feature of cancer cells. In this study, we develop a lactate-responsive drug delivery platform by targeting the Warburg effect. We design and test a gold/mesoporous silica Janus nanoparticle system as a gated drug carrier, in which the gold particles are functionalized with lactate oxidase and the silica particles are capped with α-cyclodextrin through surface arylboronate modification. In the presence of lactate, the lactate oxidase generates hydrogen peroxide, which induces the self-immolation reaction of arylboronate, leading to uncapping and drug release. Our results demonstrate greatly improved drug delivery specificity and therapeutic efficacy with this platform for the treatment of different cancers. Our findings present an effective approach for drug delivery by metabolic targeting of tumors.
Data availability
scRNA-seq data have been deposited at GEO and are publicly available as of the date of publication. Accession numbers are listed in the key resources table. Microscopy data reported in this paper will be shared by the lead contact upon request.
This paper does not report original code.
Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
Files
Enabling-tumor-specific-drug-delivery-by-targeting-the-Warburg-effect-of-cancer.pdf
Files
(20.2 MB)
| Name | Size | Download all |
|---|---|---|
|
Article md5:16c6491b9b1416bc4878c627a8935c03 |
6.2 MB | Preview Download |
|
Supplemental information files md5:a12949e9f4fbd158dc576fca965f5467 |
13.9 MB | Preview Download |
Additional details
Identifiers
- DOI
- 10.1016/j.xcrm.2024.101920
- Other
- oai:uchicago.tind.io:14409
Funding
- National Institutes of Health
- R01OD023700
- National Institutes of Health
- R21AR080761
- National Institutes of Health
- R01DA047785
- National Institutes of Health
- R01AR78555
- University of Chicago
- Technology Impact Award
- Samuel Waxman Cancer Research Foundation
- Alan B. Slifka Foundation
- Israel Cancer Fund
- Pediatric Sarcoma Grant
- Rally Foundation
- Outside the Box Grant
- University of Chicago Medicine Comprehensive Cancer Center
- Duckworth Family Commercial Promise Award
- Unknown funder
- Cancer Immunotherapy Team Science Award
- Unknown funder
- Pancreatic Cancer SPORE grant
- Unknown funder
- UCHAP pilot award
- Unknown funder
- Ullman Family Team Science Award
- Unknown funder
- 1DP2AI144245